{"id":"verteporfin-photodynamic-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Photosensitivity reactions"},{"rate":null,"effect":"Vision decrease or blurred vision"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Back pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Verteporfin is a lipophilic photosensitizer that preferentially localizes to neovascular endothelial cells and abnormal vasculature. Upon exposure to non-thermal red light (689 nm wavelength), it undergoes photochemical activation to produce singlet oxygen and free radicals, causing selective destruction of the targeted abnormal blood vessels through thrombosis and vessel occlusion.","oneSentence":"Verteporfin is a photosensitizing agent that accumulates in abnormal blood vessels and, when activated by light, generates reactive oxygen species to destroy those vessels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:31.705Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration with predominantly classic choroidal neovascularization"},{"name":"Pathologic myopia with subfoveal choroidal neovascularization"},{"name":"Polypoidal choroidal vasculopathy"}]},"trialDetails":[{"nctId":"NCT06381154","phase":"PHASE2","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-06","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":25},{"nctId":"NCT06807359","phase":"PHASE1, PHASE2","title":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","status":"RECRUITING","sponsor":"SpectraCure AB","startDate":"2025-01-06","conditions":"Prostate Cancer","enrollment":43},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT06306638","phase":"PHASE1, PHASE2","title":"Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-10-01","conditions":"Malignant Solid Neoplasm","enrollment":53},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT03033225","phase":"PHASE2","title":"Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-05-31","conditions":"Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma","enrollment":13},{"nctId":"NCT00696592","phase":"PHASE2","title":"Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration","status":"WITHDRAWN","sponsor":"University of Padova","startDate":"2007-01-31","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT03067051","phase":"PHASE1, PHASE2","title":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","status":"RECRUITING","sponsor":"SpectraCure AB","startDate":"2017-03-21","conditions":"Recurrent Prostate Cancer","enrollment":66},{"nctId":"NCT00967850","phase":"PHASE3","title":"Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2008-04","conditions":"Myopia, Choroidal Neovascularization","enrollment":56},{"nctId":"NCT00930189","phase":"PHASE2, PHASE3","title":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Subfoveal Choroidal Neovascularization","enrollment":""},{"nctId":"NCT00347399","phase":"PHASE2","title":"Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-03","conditions":"Age Related Macular Degeneration","enrollment":25},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT00390026","phase":"PHASE3","title":"The Avastin vs Visudyne for Neovascular AMD Study","status":"WITHDRAWN","sponsor":"St. Erik Eye Hospital","startDate":"2006-11","conditions":"Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT01469156","phase":"PHASE1, PHASE2","title":"Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2011-09","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":20},{"nctId":"NCT05390619","phase":"NA","title":"Different Doses of vPDT in the Treatment of cCSC","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2020-01-01","conditions":"Central Serous Chorioretinopathy, Therapy, Photodynamic","enrollment":100},{"nctId":"NCT02587767","phase":"NA","title":"577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09","conditions":"Acute Central Serous Chorioretinopathy","enrollment":68},{"nctId":"NCT02452840","phase":"","title":"Photodynamic Therapy for PDA in NV AMD","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-05-11","conditions":"Neovascular Age-related Macular Degeneration, Macular Degeneration","enrollment":100},{"nctId":"NCT02120950","phase":"PHASE4","title":"Aflibercept in Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-05-29","conditions":"Neovascular Macular Degeneration","enrollment":333},{"nctId":"NCT00473642","phase":"PHASE4","title":"Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Oklahoma State University Center for Health Sciences","startDate":"2007-05","conditions":"Age-Related Maculopathy, Choroidal Neovascularization","enrollment":31},{"nctId":"NCT04429139","phase":"NA","title":"Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-02-01","conditions":"Retinoblastoma","enrollment":8},{"nctId":"NCT02495181","phase":"PHASE4","title":"Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2015-11-23","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":50},{"nctId":"NCT03079141","phase":"PHASE4","title":"Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2017-02-20","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":107},{"nctId":"NCT04075188","phase":"NA","title":"Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2017-09-18","conditions":"Choroidal Neovascularization, Choroid Disease","enrollment":17},{"nctId":"NCT02821520","phase":"PHASE4","title":"Initial Versus Delayed PDT Combination With Conbercept in PCV","status":"COMPLETED","sponsor":"The Eye Hospital of Wenzhou Medical University","startDate":"2017-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":80},{"nctId":"NCT01846273","phase":"PHASE4","title":"Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-07","conditions":"Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy","enrollment":321},{"nctId":"NCT02702700","phase":"PHASE1","title":"Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2016-01","conditions":"Pleural Effusion, Malignant","enrollment":1},{"nctId":"NCT03692169","phase":"","title":"The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC","status":"UNKNOWN","sponsor":"Jin Chen-jin","startDate":"2016-10-31","conditions":"Central Serous Chorioretinopathy","enrollment":60},{"nctId":"NCT02072408","phase":"PHASE4","title":"Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2014-02","conditions":"Polypoidal Choroidal Vasculopathy Without Active Polyp","enrollment":46},{"nctId":"NCT02939274","phase":"PHASE2","title":"An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer","status":"UNKNOWN","sponsor":"Rogers Sciences Inc.","startDate":"2016-10","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT03497000","phase":"NA","title":"Effects of OCTA-guided PDT in Acute CSC","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2017-09-01","conditions":"Central Serous Chorioretinopathy, Tomography, Optical Coherence","enrollment":23},{"nctId":"NCT02872064","phase":"NA","title":"Treatment of Primary Breast Cancer Using PDT","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-01","conditions":"Breast Neoplasms","enrollment":12},{"nctId":"NCT03459144","phase":"NA","title":"Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2012-12-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT02464761","phase":"PHASE1","title":"Photodynamic Therapy for the Treatment of Vertebral Metastases","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2011-06","conditions":"Vertebral Metastases","enrollment":30},{"nctId":"NCT01797861","phase":"PHASE4","title":"Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-12","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":140},{"nctId":"NCT02457026","phase":"NA","title":"Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2016-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT00100009","phase":"PHASE3","title":"Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2004-12-09","conditions":"Macular Degeneration","enrollment":30},{"nctId":"NCT01482910","phase":"PHASE3","title":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12","conditions":"Macular Degeneration","enrollment":304},{"nctId":"NCT01574430","phase":"PHASE4","title":"Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2010-12","conditions":"Central Serous Chorioretinopathy","enrollment":131},{"nctId":"NCT02799992","phase":"NA","title":"Pseudo-PDT in Central Serous Chorioretinopathy","status":"UNKNOWN","sponsor":"Università degli Studi di Brescia","startDate":"2016-06","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":22},{"nctId":"NCT00729846","phase":"PHASE2","title":"Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2006-05","conditions":"Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema","enrollment":22},{"nctId":"NCT00242580","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":111},{"nctId":"NCT00423189","phase":"PHASE4","title":"Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"David M. Brown, M.D.","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":7},{"nctId":"NCT01032109","phase":"NA","title":"Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2006-10","conditions":"Age-related Macular Degeneration","enrollment":45},{"nctId":"NCT00802126","phase":"PHASE1","title":"Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2007-11","conditions":"Myopia","enrollment":16},{"nctId":"NCT01746875","phase":"NA","title":"A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes","status":"TERMINATED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-02","conditions":"Macular Degeneration, Retinal Detachment","enrollment":9},{"nctId":"NCT01666236","phase":"PHASE4","title":"Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy","status":"WITHDRAWN","sponsor":"Federal University of São Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization, Retinal Pigment Epithelial Detachment","enrollment":""},{"nctId":"NCT01630863","phase":"NA","title":"The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","status":"UNKNOWN","sponsor":"Yeungnam University College of Medicine","startDate":"2012-06","conditions":"Central Serous Chorioretinopathy","enrollment":45},{"nctId":"NCT00041483","phase":"PHASE3","title":"Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2002-06","conditions":"Macular Degeneration","enrollment":530},{"nctId":"NCT00061594","phase":"PHASE3","title":"A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-05","conditions":"Macular Degeneration","enrollment":426},{"nctId":"NCT01256580","phase":"NA","title":"Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD","status":"WITHDRAWN","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2010-08","conditions":"Choroidal Neovascularization, Myopia, Punctate Inner Choroidopathy (PIC)","enrollment":""},{"nctId":"NCT00007969","phase":"PHASE1, PHASE2","title":"Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2000-10","conditions":"Melanoma (Skin)","enrollment":""},{"nctId":"NCT01974622","phase":"NA","title":"ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study","status":"UNKNOWN","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2013-04","conditions":"Retinal Vascular Disorders","enrollment":30},{"nctId":"NCT01968486","phase":"PHASE1","title":"Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2012-06","conditions":"Myopia, Degenerative","enrollment":60},{"nctId":"NCT00002647","phase":"PHASE1","title":"Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors","status":"UNKNOWN","sponsor":"Medical College of Wisconsin","startDate":"1994-05","conditions":"Brain and Central Nervous System Tumors, Metastatic Cancer","enrollment":24},{"nctId":"NCT00056823","phase":"PHASE1, PHASE2","title":"Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-03","conditions":"Age-Related Maculopathy","enrollment":168},{"nctId":"NCT01325181","phase":"PHASE1, PHASE2","title":"Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Jang Won Heo","startDate":"2009-07","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":34},{"nctId":"NCT00211458","phase":"PHASE2","title":"Treatment of Age-Related Macular Degeneration With Anecortave Acetate","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2005-09","conditions":"Macular Degeneration","enrollment":""},{"nctId":"NCT00211419","phase":"PHASE1","title":"Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"","conditions":"Maculopathy, Age-Related","enrollment":""},{"nctId":"NCT00570193","phase":"PHASE1, PHASE2","title":"Photodynamic and Pharmacologic Treatment of CNV","status":"COMPLETED","sponsor":"Mid-Atlantic Retina Consultations, Inc.","startDate":"2006-12","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":41},{"nctId":"NCT00726973","phase":"NA","title":"Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)","status":"WITHDRAWN","sponsor":"Lahey Clinic","startDate":"2006-12","conditions":"Macular Edema","enrollment":""},{"nctId":"NCT01570608","phase":"PHASE3","title":"Lucentis KAV Study","status":"COMPLETED","sponsor":"The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery","startDate":"2007-03","conditions":"Age Related Macular Degeneration","enrollment":51},{"nctId":"NCT00680498","phase":"PHASE4","title":"Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment","status":"COMPLETED","sponsor":"Illinois Retina Associates","startDate":"2007-02","conditions":"Age-Related Macular Degeneration","enrollment":10},{"nctId":"NCT00376701","phase":"PHASE2","title":"Combination Therapy for Age-Related Macular Degeneration.","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-09","conditions":"Age Related Macular Degeneration","enrollment":103},{"nctId":"NCT01434095","phase":"NA","title":"Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"Surugadai Nihon University Hospital","startDate":"2008-10","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":16},{"nctId":"NCT01019668","phase":"NA","title":"Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy","status":"COMPLETED","sponsor":"Shin Kong Wu Ho-Su Memorial Hospital","startDate":"2008-11","conditions":"Central Serous Chorioretinopathy","enrollment":24},{"nctId":"NCT00492284","phase":"PHASE2","title":"Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2007-07","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":162},{"nctId":"NCT01360151","phase":"NA","title":"Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2011-02","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":16},{"nctId":"NCT00433017","phase":"PHASE2, PHASE3","title":"Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-05","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":255},{"nctId":"NCT00436553","phase":"PHASE3","title":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":321},{"nctId":"NCT00674323","phase":"PHASE4","title":"Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":61},{"nctId":"NCT00331435","phase":"PHASE4","title":"PDT Study for Exudative AMD With PCV","status":"COMPLETED","sponsor":"Ophthalmic PDT Study Group","startDate":"2006-06","conditions":"Age Related Macular Degeneration","enrollment":113},{"nctId":"NCT00049959","phase":"PHASE3","title":"Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.","status":"TERMINATED","sponsor":"QLT Inc.","startDate":"","conditions":"Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome","enrollment":""},{"nctId":"NCT00390208","phase":"PHASE2","title":"Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2006-08","conditions":"Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT00464347","phase":"PHASE2","title":"TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration","status":"TERMINATED","sponsor":"National Eye Institute (NEI)","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT00413829","phase":"PHASE2","title":"Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-10","conditions":"Age Related Macular Degeneration","enrollment":20},{"nctId":"NCT00546936","phase":"PHASE2","title":"Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis","status":"UNKNOWN","sponsor":"Barnes Retina Institute","startDate":"2007-10","conditions":"Presumed Ocular Histoplasmosis (POHS)","enrollment":30},{"nctId":"NCT00429962","phase":"PHASE3","title":"Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2006-07","conditions":"Choroidal Neovascularization, Age-Related Macular Degeneration","enrollment":40},{"nctId":"NCT00813891","phase":"PHASE4","title":"Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"Macular Degeneration, Visual Acuity","enrollment":180},{"nctId":"NCT00471406","phase":"NA","title":"Photodynamic Therapy With Verteporfin for Corneal Neovascularization","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"","conditions":"Corneal Neovascularization","enrollment":""},{"nctId":"NCT00359164","phase":"PHASE2","title":"Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2006-07","conditions":"Macular Degeneration","enrollment":36},{"nctId":"NCT00288561","phase":"PHASE2","title":"Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Age-Related Macular Degeneration (ARMD)","enrollment":""},{"nctId":"NCT00455871","phase":"NA","title":"Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD","status":"UNKNOWN","sponsor":"Barnes Retina Institute","startDate":"2007-04","conditions":"Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT00211445","phase":"PHASE2","title":"Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)","status":"COMPLETED","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2002-07","conditions":"Chronic Central Serous Chorioretinopathy","enrollment":11},{"nctId":"NCT00426998","phase":"PHASE2","title":"Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD","status":"COMPLETED","sponsor":"Retinal Consultants Medical Group","startDate":"2006-04","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":30},{"nctId":"NCT00134667","phase":"PHASE4","title":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Eyetech Pharmaceuticals","startDate":"2005-03","conditions":"Age-Related Macular Degeneration","enrollment":360},{"nctId":"NCT00370539","phase":"PHASE3","title":"Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-09","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT00272766","phase":"NA","title":"Macugen for Histoplasmosis","status":"TERMINATED","sponsor":"Barnes Retina Institute","startDate":"2006-02","conditions":"Ocular Histoplasmosis, Choroidal Neovascularization","enrollment":24},{"nctId":"NCT00135837","phase":"PHASE4","title":"Photodynamic Therapy in Occult-Only Lesions (POOL)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-06","conditions":"Age-Related Macular Degeneration","enrollment":202},{"nctId":"NCT00121407","phase":"PHASE3","title":"Visudyne® in Occult (VIO)","status":"COMPLETED","sponsor":"QLT Inc.","startDate":"2002-03","conditions":"Macular Degeneration","enrollment":364}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":316,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Visudyne"],"phase":"marketed","status":"active","brandName":"Verteporfin Photodynamic Therapy","genericName":"Verteporfin Photodynamic Therapy","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Verteporfin is a photosensitizing agent that accumulates in abnormal blood vessels and, when activated by light, generates reactive oxygen species to destroy those vessels. Used for Age-related macular degeneration with predominantly classic choroidal neovascularization, Pathologic myopia with subfoveal choroidal neovascularization, Polypoidal choroidal vasculopathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}